Novartis strikes deal with Schrödinger

Novartis has entered a 3-year partnership with Schrödinger, a computational chemistry services company, to discover new drugs. Novartis will gain access to Schrödinger’s wide range of drug discovery software. Schrödinger will receive $150 million up front and will be eligible for $2.3 billion in milestone payments and royalties. Both companies will share responsibility for discovering drugs for targets the firms have yet to disclose.